Skip to content
10-Q

Quarterly Report

NUTRA PHARMA CORP. NPHC

0001493152-26-009667

← back to feed
Filed
Mar 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Mar 11, 2026 7.16B sh
Long Term Debt Q1 2025 · Mar 31, 2025 $139.34K
Long Term Debt Q1 2025 · Dec 31, 2024 $140.22K
Short Term Investments Q1 2025 · Mar 31, 2025 $17.6K
Short Term Investments Q1 2025 · Dec 31, 2024 $17.6K
Current Liabilities Q1 2025 · Mar 31, 2025 $16.85M
Current Liabilities Q1 2025 · Dec 31, 2024 $15.27M
Total Liabilities Q1 2025 · Mar 31, 2025 $16.99M
Total Liabilities Q1 2025 · Dec 31, 2024 $15.41M
Current Assets Q1 2025 · Mar 31, 2025 $552.12K
Current Assets Q1 2025 · Dec 31, 2024 $374.84K
Total Assets Q1 2025 · Mar 31, 2025 $775.18K
Total Assets Q1 2025 · Dec 31, 2024 $599.5K
Sga Expense Q1 2025 · Mar 31, 2025 $418.15K
Sga Expense Q1 2025 · Mar 31, 2024 $330.51K
Cost Of Revenue Q1 2025 · Dec 31, 2024 $240.56K
Shares Diluted Q1 2025 · Mar 31, 2024 7.64B sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$171.2K
Stockholders Equity Q1 2025 · Mar 31, 2024 −$14.19M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$13.77M
Eps Diluted Q1 2025 · Mar 31, 2024 $0.00
Eps Basic Q1 2025 · Mar 31, 2024 $0.00
Net Income Q1 2025 · Mar 31, 2024 −$426.93K
Operating Income Q1 2025 · Mar 31, 2024 −$295.31K
Gross Profit Q1 2025 · Mar 31, 2024 $35.2K
Revenue Q1 2025 · Mar 31, 2024 $37.73K